Novartis reported a strong performance in Q2 with struggling Sandoz (+3% vs -2% on Q1 19) coming as a positive surprise. The innovative pharma business also continued to grow at a healthy pace, driven by the new drugs. Pricing relief stood out in all the businesses, with a bigger impact at Sandoz. FX had a negative impact of 4ppts. The good trajectory continued on the profitability side as well, prompting another outlook upgrade.
19 Jul 2019
Another stellar quarter
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Another stellar quarter
Novartis AG (0QLR:LON) | 0 0 0.7% | Mkt Cap: 208,186m
- Published:
19 Jul 2019 -
Author:
Kamla Singh -
Pages:
3
Novartis reported a strong performance in Q2 with struggling Sandoz (+3% vs -2% on Q1 19) coming as a positive surprise. The innovative pharma business also continued to grow at a healthy pace, driven by the new drugs. Pricing relief stood out in all the businesses, with a bigger impact at Sandoz. FX had a negative impact of 4ppts. The good trajectory continued on the profitability side as well, prompting another outlook upgrade.